Obinutuzumab Biosimilar - Research Grade

Target: CD20.

Specificity: Detects human CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Obinutuzumab/afutuzumab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: Obinutuzumab biosimilar is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B cells. The molecular mass of the antibody is approximately 150 kDa. it is produced by mammalian cell (CHO) suspension culture. It was engineered for reduced fucose content as compared to a typical IgG1 produced in CHO cells.

Concentration: 1.0 - 5.0 mg/ml.

Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Purity: >95% by SDS-PAGE and HPLC.

Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.